
Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

Abivax SA raises €130m to advance obefazimod to Phase III
Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

New polymer can stop biofilm formation
The acrylate co-polymer reported by Jean-Frédéric Dubern and colleagues in Science Advances (doi: 10.1126/sciadv.add7474) have the potential to...

Evonetix extends Series B financing to US$54m
According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

Noema Pharma AG closes Series B financing
CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as...